Naltrexone
Complex Regional Pain Syndrome Type 1
Explore 4 assets in Complex Regional Pain Syndrome Type 1 →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Hospital for Special Surgery, New York
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06306157CT.gov Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Complex Regional Pain Syndrome Type 1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Naltrexone (this asset) | Hospital for Special Surgery, New York | Approved | BB · 64 |
| Lidocaine | Hospices Civils de Lyon | P2/3 | B |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Hospices Civils de Lyon | P2/3 | B |
| Neurotropin | National Institute of Nursing Research (NINR) | P2 | CCC |
| Incobotulinumtoxin-A | Bo Biering-Soerensen | N/A | NR |
Other indications for Naltrexone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alcohol Dependence | — | P4 | BBB · 79 |
| Osteoarthritis | — | P4 | BBB · 75 |
| Rheumatoid Arthritis | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Naltrexone in Complex Regional Pain Syndrome Type 1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/naltrexone-complex-regional-pain-syndrome-type-1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →